News
J&J files FcRn blocker nipocalimab for generalised myasthenia gravis (gMG) in US, setting up a challenge to rival drugs from Argenx and UCB ...
Johnson & Johnson has its first regulatory approval for FcRn blocker Imaavy, getting a green light in the US for generalised myasthenia gravis (gMG).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback